3 Years of Tralokinumab Treatment Provides Long-Term Disease Control As Demonstrated by Clinically Meaningful Outcomes in Moderate-to-Severe Atopic Dermatitis. J of Skin 2022, 6 (6), s78. https://doi.org/10.25251/skin.6.supp.78.